• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    5/21/24 12:31:03 PM ET
    $AKAN
    $AONC
    $AXDX
    $BDRX
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $AKAN alert in real time by email

    Gainers

    • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million.
    • Genelux (NASDAQ:GNLX) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million.
    • Bionomics (NASDAQ:BNOX) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million.
    • Xylo Technologies (NASDAQ:XYLO) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million.
    • Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 16.25% to $1.02. The market value of their outstanding shares is at $22.4 million.

    Losers

    • Dare Bioscience (NASDAQ:DARE) stock fell 32.8% to $0.41 during Tuesday's regular session. The company's market cap stands at $41.4 million.
    • American Oncology Network (NASDAQ:AONC) shares declined by 27.76% to $1.9. The company's market cap stands at $19.3 million. As per the news, the Q1 earnings report came out 4 days ago.
    • Akanda (NASDAQ:AKAN) shares fell 25.44% to $0.1. The market value of their outstanding shares is at $3.4 million.
    • Scorpius Holdings (AMEX:SCPX) stock fell 25.13% to $0.12. The market value of their outstanding shares is at $7.8 million.
    • Sonoma Pharmaceuticals (NASDAQ:SNOA) shares decreased by 20.67% to $0.18. The company's market cap stands at $2.8 million.
    • GT Biopharma (NASDAQ:GTBP) shares fell 20.4% to $6.21. The company's market cap stands at $8.5 million. As per the news, the Q1 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AKAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKAN
    $AONC
    $AXDX
    $BDRX

    CompanyDatePrice TargetRatingAnalyst
    Genelux Corporation
    $GNLX
    10/21/2025$16.00Buy
    Lake Street
    GT Biopharma Inc.
    $GTBP
    12/2/2024$11.00Buy
    ROTH MKM
    Genelux Corporation
    $GNLX
    10/29/2024$8.00Buy
    Guggenheim
    Genelux Corporation
    $GNLX
    8/28/2024$10.00Buy
    ROTH MKM
    Biodexa Pharmaceuticals plc American Depositary Shs
    $BDRX
    2/8/2024$8.00Buy
    Ladenburg Thalmann
    Genelux Corporation
    $GNLX
    11/27/2023$35.00Buy
    H.C. Wainwright
    Bionomics Limited
    $BNOX
    9/28/2023$7.00 → $10.00Buy
    Maxim Group
    Bionomics Limited
    $BNOX
    9/28/2023$8.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $AKAN
    $AONC
    $AXDX
    $BDRX
    SEC Filings

    View All

    Amendment: SEC Form F-1/A filed by Akanda Corp.

    F-1/A - AKANDA CORP. (0001888014) (Filer)

    3/20/26 5:17:52 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 424B5 filed by Genelux Corporation

    424B5 - GENELUX Corp (0001231457) (Filer)

    3/19/26 5:30:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Genelux Corporation

    S-8 - GENELUX Corp (0001231457) (Filer)

    3/19/26 5:27:03 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Parker Stephen Barry

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/20/26 5:19:51 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:18 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs

    3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)

    3/18/26 9:30:20 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on GT Biopharma with a new price target

    ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00

    12/2/24 10:00:20 AM ET
    $GTBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XACIATO issued to DARE BIOSCIENCE INC

    Submission status for DARE BIOSCIENCE INC's drug XACIATO (ORIG-1) with active ingredient CLINDAMYCIN PHOSPHATE has changed to 'Approval' on 12/07/2021. Application Category: NDA, Application Number: 215650, Application Classification: Type 5 - New Formulation or New Manufacturer

    12/7/21 12:35:25 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

    March 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial

    3/23/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    On National Viagra Day, Women Finally Claim Their Turn:

    SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Every year on March 27th, National Viagra Day celebrates a drug that transformed sexual health for millions of men. Today, Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, is declaring that the conversation is long overdue for an upgrade — and that the future of women's sexual wellness is finally here. Introducing DARE to PLAY™ Sildenafil Cream — the first topical arousal cream clinically studied and developed specifically for women. Where Viagra® was designed for men, DARE to PLAY™ was designed with women in mind

    3/23/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $40,650 worth of Class A Shares (29,036 units at $1.40) and sold $10,150 worth of Class A Shares (7,868 units at $1.29) (SEC Form 4)

    4 - AKANDA CORP. (0001888014) (Issuer)

    1/20/26 2:07:19 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

    4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

    12/3/24 8:48:49 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

    January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is delighted to announce the promotion of Fiona Sharp to Chief Financial Officer and Company Secretary along with her election to the Board of Directors of the Company with immediate effect. Ms Sharp is a senior finance professional having joined the Company as Group Financial Controller in December 2019. During her tenure, she has consistentl

    1/5/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Financials

    Live finance-specific insights

    View All

    Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026

    SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

    3/20/26 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and DARE to RECLAIM™ Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Ea

    11/13/25 4:01:00 PM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

    SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

    11/6/25 8:00:00 AM ET
    $DARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKAN
    $AONC
    $AXDX
    $BDRX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care